Skip to main content
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. — Investor Relations & Filings

Ticker · MAZE ISIN · US5787841007 US Manufacturing
Open in API
Filings indexed 139 across all filing types
Latest filing 2025-02-04 Director's Dealing
Country US United States of America
Listing US MAZE

About Maze Therapeutics, Inc.

https://www.mazetx.com/

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that harnesses insights from human genetics to develop novel, small molecule precision medicines. The company utilizes its proprietary Compass platform, which leverages variant functionalization, to identify and validate new therapeutic targets. Maze's strategy focuses on designing medicines that imitate the effects of rare, naturally occurring, protective genetic variants to address common diseases with significant unmet medical needs. Its pipeline is focused on advancing treatments for renal and cardio-metabolic indications, with a lead program targeting APOL1-mediated kidney disease (AMKD).

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-02-04 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is a registration statement used to register securities to be offered to employees under employee benefit plans. It includes detailed information about equity incentive plans and employee stock purchase plans, indemnification provisions, and exhibits related to corporate governance documents. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a mere announcement but a full registration statement.
2025-01-31 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by Maze Therapeutics, Inc. It includes extensive information typical of a registration statement or prospectus, such as offering details, risk factors, management discussion and analysis, business overview, executive compensation, and financial statements. The presence of underwriting details, offering price, and shares offered confirms this is a capital raising document. The document is not an annual report, earnings release, or any other report type but rather a capital markets filing related to financing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-01-31 English
Regulatory Filings 2025
Regulatory Filings
2025-01-31 English
3
Director's Dealing
2025-01-31 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the offering, the registrant, legal counsel, and signatures of officers and directors. It is not a financial report like an annual or quarterly report, nor is it an earnings release or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 7,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2025-01-31 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.